Found: 10
Select item for more details and to access through your institution.
Vasculogenic mimicry in small cell lung cancer.
- Published in:
- Nature Communications, 2016, v. 7, n. 11, p. 13322, doi. 10.1038/ncomms13322
- By:
- Publication type:
- Article
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 8, p. 1377, doi. 10.1038/s41416-024-02614-w
- By:
- Publication type:
- Article
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
- Published in:
- Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-021-01196-x
- By:
- Publication type:
- Article
Side Population in Human Non-Muscle Invasive Bladder Cancer Enriches for Cancer Stem Cells That Are Maintained by MAPK Signalling.
- Published in:
- PLoS ONE, 2012, v. 7, n. 11, p. 1, doi. 10.1371/journal.pone.0050690
- By:
- Publication type:
- Article
Human α<sub>2</sub>β<sub>1</sub><sup>HI</sup> CD133<sup>+VE</sup> Epithelial Prostate Stem Cells Express Low Levels of Active Androgen Receptor.
- Published in:
- PLoS ONE, 2012, v. 7, n. 11, p. 1, doi. 10.1371/journal.pone.0048944
- By:
- Publication type:
- Article
In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells.
- Published in:
- Journal of Pathology, 2011, v. 225, n. 2, p. 181, doi. 10.1002/path.2965
- By:
- Publication type:
- Article
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00571-w
- By:
- Publication type:
- Article
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00571-w
- By:
- Publication type:
- Article